27 results about "Glycerol phosphate" patented technology

The present invention relates to a non-invasive test for the detection of deep endometriosis. Particularly, although not exclusively, aspects of the present invention relate to one or more glycolysis-associated biomarkers (e.g., phosphoglycerate mutase 1 (PGAM1), Enolase-1 (ENO1), phosphofructokinase-1 (PFKP) and / or Hexokinase) and / or cytokines associated with aerobic glycolysis (e.g., IL-6 and / or TGF-β) which can be used to determine the likelihood of a subject having deep endometriosis based on a sample obtained from the subject.

Recombinant microorganism in which a gene encoding a transcriptional repressor of the glycine cleavage system, pyruvate formate lyase or phosphoglycerate dehydrogenase, is attenuated or deleted from a host microorganism with a formic acid assimilation pathway, a ppsR gene encoding a phosphoenolpyruvate synthase regulatory protein, or a purT gene encoding a phosphoribosylglycinamide formyltransferase, is attenuated or deleted, a gcvTHP gene, consisting of the gcvT gene, the gcvH gene and the gcvP gene, which encodes an enzyme involved in a glycine cleavage system reaction in which host microorganism with the formic acid assimilation pathway is highly expressed, and a gene encoding formate tetrahydrofolate ligase, methenyl tetrahydrofolate cyclohydrolase or methylene tetrahydrofolate dehydrogenase is introduced into the host microorganism via the formic acid assimilation pathway.

This invention belongs to the field of bioengineering, specifically disclosing a 3-phosphoglycerate dehydrogenase mutant with improved enzyme activity and thermostability. Compared to the wild-type 3-phosphoglycerate dehydrogenase from *Corynebacterium glutamicum*, the mutant contains one mutation from among P85Q, D365Y, A389T, M196V, A183V, and I231V. Enzyme activity assays after induced expression and purification showed that the mutant's enzyme activity was 1.5–3.6 times higher than the wild type, and its thermostability was significantly improved. Therefore, the beneficial mutant provided by this invention lays a good foundation for the industrial fermentation production of L-serine and L-cysteine.

The present invention discloses an antibacterial compound of Formula 1 or pharmaceutically acceptable salt thereof:wherein X is CH, S, CH—NH2;R1 is C1-C8 alkyl, substituted alkyl, alkyl amine, substituted amine; preferably R1 is methyl, ethyl, propyl, butyl, pentyl, isopropyl, isobutyl, methyl amine, ethylamine, propylamine, isopropyl amine, isobutylamine, N-ethylprop-2-yn-1-amine, N-isopropyl propane-1,3-diamine, N1-isopropyl ethane-1,3-diamine, 1-butyl-2-methylguanidine, N1-ethyl-N1-propylethane-1,2-diamine, cyclobutyamine, phosphate, sulphate;R2 is hydrogen, alkyl, substituted alkyl; preferably R2 is methyl, propyl, isopropyl;R3 is hydrogen, alkyl, substituted alkyl; and preferably R3 is methyl, propyl, isopropyl.The Formula 1 or pharmaceutically acceptable salt thereof is an imidazole glycerol phosphate dehydratase (IGPD) inhibitor and treats or prevents or ameliorates tuberculosis.

The object of the present invention is a liposomal composition comprising the tripeptide glycyl-L-histidyl-L-lysine-copper (GHK-Cu) complex, wherein said complex is encapsulated in lipid carrier A comprising 19 to 39 wt % of the sodium salt of 1,2-distearoyl-sn-glycero-3- phosphoglycerol (DSPG-Na), 29 to 42 wt % of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 24 to 41 wt % of cholesterol, or in lipid carrier B comprising 16 to 21 wt % of N- [carbonyl-methoxy(polyethylene glycol)-2000]-1,2-distearoyl-sn-glycero-3- phosphoethanolamine (DSPE-PEG2000), 48 to 63 wt % of hydrogenated soybean phosphatidylcholine (HSPC) and 16 to 36 wt % of cholesterol. A further object of the invention is a method for preparing the liposomal composition of the invention and its use as a component of a cosmetic formulation.

The invention relates to the technical field of genetic engineering, in particular to a recombinant bacterium for high-yield serine and application of the recombinant bacterium in fermentation production of serine. The ptsI gene of escherichia coli is knocked out, a glucose PTS system is blocked, glucose transport and phosphorylation and PEP-pyruvic acid associated reaction are relieved, and pyruvic acid is synthesized by reducing serine synthesis precursor 3-phosphoglyceric acid branches. Growth adaptive evolution is further carried out on escherichia coli with the ptsI gene knocked out, an obtained mutant strain is sequenced, the mutation condition is shown in a table 2, and finally the growth rate accelerating chassis bacterium is obtained. Afterwards, by enhancing the expression serine key genes serA, serB and serC of the mutant strain and knocking out serine degradation pathway genes sdaA, sdaB and tdcG, the engineering bacterium for fermentation production of serine is constructed, and the serine yield of the engineering bacterium is remarkably improved.

The invention provides a genetically engineered recombinant Klebsiella michiganensis having reduced or inactivated glucose-specific PTS transport system, glycerol kinase, glycerol dehydrogenase, alcohol dehydrogenase, acetolactate synthase, acetolactate decarboxylase, fumarate reductase and 3-phosphoglyceraldehyde dehydrogenase, having, preferably enhanced, NADPH-dependent alcohol dehydrogenase, diol dehydratase, 3-phosphoglycerate dehydrogenase and 3-phosphoglycerate phosphatase activities, methods of making said recombinant Klebsiella michiganensis, and uses and methods of producing 1,3-propanediol using said recombinant Klebsiella michiganensis.

This invention belongs to the technical field of creatine kinase detection kits, specifically relating to a reagent, kit, and application for detecting creatine kinase, including a buffer, creatine phosphate, glycerol, glycerol kinase, glycerol phosphate oxidase, peroxidase, and a chromogenic agent, and also containing a CK activating reducing agent, as well as perfluorinated and polyfluoroalkyl substances. The CK activating reducing agent is a sulfur-containing reducing agent. This invention can improve the accuracy of detection.

The invention provides a chimeric recombinant vector containing SCW10 signal peptide, recombinant pichia pastoris engineering bacteria and application of the recombinant pichia pastoris engineering bacteria in expression of glycoprotein S.rug.-PGK, and belongs to the technical field of phosphoglycerate kinase production. According to the chimeric recombinant vector containing the SCW10 signal peptide, the chimeric recombinant vector is obtained by chimerizing the N end of the SCW10 signal peptide and the C end sequence of alpha-factor signal peptide in the recombinant vector, and the nucleotide sequence of the SCW10 signal peptide is as shown in SEQ ID NO.1; the recombinant vector is a recombinant vector containing phosphoglycerate kinase S.rug.-PGK from Stropharia rugoso-annulata, and the amino acid sequence of the S.rug.-PGK is as shown in SEQ ID NO. 2. The chimeric recombinant vector containing the SCW10 signal peptide constructed by the invention can be successfully transformed into pichia pastoris, so that the purpose of efficiently secreting and producing a large amount of PGK by the pichia pastoris is achieved.

The present application provides a recombinant E. coli for synthesizing heme and derivatives thereof, wherein the recombinant E. coli is knocked out of genes such as pyruvate oxidase poxB, pyruvate formate-lyase pflB and protoporphyrinogen peroxidase yfeX, and meanwhile, the genes such as phosphopyruvate carboxylase ppc, glycerol transporter glpF and 3-phosphoglycerate dehydrogenase glpD are enhanced, and the genes such as 5-aminovaleryl-CoA synthase hemA and ferrous chelatase hemH are introduced, so that the recombinant E. coli can synthesize heme and derivatives thereof by using glycerol as a raw material, and has application prospects in the field of biological manufacturing.

The application discloses a D-3-phosphoglycerate dehydrogenase mutant and application thereof in improving L-tryptophan, and belongs to the technical field of biology.The technical problem to be solved by the application is how to improve the yield of L-tryptophan.Based on this, the application provides the D-3-phosphoglycerate dehydrogenase mutant and application thereof in improving the yield of L-tryptophan, wherein the D-3-phosphoglycerate dehydrogenase mutant is a protein with an amino acid sequence comprising SEQ ID NO:3.The application can be used for improving the yield of L-tryptophan of Escherichia coli.

The invention discloses a D-3-phosphoglycerate dehydrogenase mutant and application of the D-3-phosphoglycerate dehydrogenase mutant in improving L-tryptophan, and belongs to the technical field of biology. The technical problem to be solved by the invention is how to improve the yield of L-tryptophan. On the basis, the invention provides a D-3-phosphoglycerate dehydrogenase mutant and an application of the D-3-phosphoglycerate dehydrogenase mutant in improving the yield of L-tryptophan, and the D-3-phosphoglycerate dehydrogenase mutant is a protein of which the amino acid sequence comprises SEQ ID NO: 3. The method can be used for improving the yield of the L-tryptophan of the Escherichia coli.

This invention provides a multi-enzyme cascade catalytic reaction system and its application, belonging to the field of enzyme catalysis production technology. Using glycerol as a raw material, it includes a first module, a second module, and a third module. The first module involves the production of glyceric acid from glycerol under the catalysis of alditol oxidase. The second module contains glyceric acid, ATP, and NAD+. + L-glutamic acid is synthesized into phosphoserine via glycerate kinase, D-3-phosphoglycerate dehydrogenase, and phosphoserine transaminase. The third module involves phosphoserine and nucleophiles being catalyzed by phosphoserine thioylase to synthesize L-cysteine ​​or a non-natural L-α-amino acid. The multi-enzyme cascade catalytic reaction system provided by this invention can catalyze a variety of nucleophiles, yields high products, is low in cost, causes minimal environmental pollution, and is easily industrialized.

The present invention generally relates to methods of biological reduction of metal-cyanide complexes after metal-cyanidation and methods of biologically hydrolysing cyanide. More particularly, the present invention allows the engineering of an integrated synthetic lixiviant biological system to be housed within a synthetic host (such as the cyanogenic Chromobacterium violaceum) for efficient precious metal recovery and toxic metal remediation of electronic waste; with up to four main components / modules in the design and engineering of the synthetic host: 1) synthetic cyanogenesis; 2) synthetic metal recovery; 3) synthetic cyanolysis; and 4) synthetic circuits for lixiviant biology. Bacteria capable of reducing ionic metal to ionic metal (such as gold or silver) as nanoparticles, comprising mercury(11) reductase (MerA) comprising a substitution mutation at position V317, Y441, C464, A323D, A414E, G415I, E416C, L417I, I418D, or A422N, are also disclosed. Processes of synthetic cyanide lixiviant production using genetically engineered bacterium transformed with a heterologous hydrogen cyanide synthase gene and a heterologous 3-phosphoglycerate dehydrogenase mutant gene are also disclosed. Processes of synthetic cyanolysis using a genetically engineered bacterium transformed with a heterologous nitrilase gene are also disclosed.

The application belongs to the technical field of genetic engineering, and particularly relates to a phosphoglycolate dehydrogenase mutant and application thereof in L-serine production. The mutant contains a mutation of the 370th amino acid compared with a protein with an amino acid sequence as shown in SEQ ID NO:1. The mutant protein releases feedback inhibition, and the catalytic activity is significantly improved compared with the parent enzyme, thereby promoting the production of L-serine catalyzed by the phosphoglycolate dehydrogenase, and providing a new synthetic route and an engineering bacterium for the production of L-serine.

This invention provides a recombinant bacterium and its applications. After specific genetic engineering modifications, this recombinant bacterium can synthesize polyhydroxybutyrate (PHB) using one-carbon compounds such as methanol or carbon dioxide as a carbon source. Specifically, the metabolic pathway of the recombinant bacterium, after optimization, enables the efficient synthesis of PHB from methanol as a raw material via metabolic intermediates such as formaldehyde, 3-phosphoglyceric acid, and acetyl-CoA. The recombinant bacterium constructed in this invention can effectively utilize low-cost carbon sources such as methanol or carbon dioxide to produce PHB, and has promising prospects for industrial application.

This invention discloses a magnetic nanoprobe and kit for assessing postherpetic neuralgia. The magnetic nanoprobe is a complex formed by thiolized carbonized polymer dots, a chelating agent, superparamagnetic molecules, and 2-phospho-D-glyceric acid. 2-phospho-D-glyceric acid specifically reacts with NSE, dehydrating to generate phosphoenolpyruvate and releasing water molecules. The magnetic nanoprobe is specific for NSE and can be used for assessing postherpetic neuralgia. The kit includes the magnetic nanoprobe and instructions, and can determine the NSE marker content in a single sample, with a detection limit better than 1 pg / mL, thereby achieving effective assessment of postherpetic neuralgia.

The present disclosure relates to the production of oligosaccharides, especially Human milk Oligosaccharides (HMOs) using a genetically engineered cell which has decreased or total loss of function of phosphoglycerol transferase I and II and / or phosphoethanolamine transferase and / or glucans biosynthesis protein C to reduce oligosaccharide by-products and / or increase oligosaccharide production.

The application belongs to the technical field of medicines, and particularly relates to a kind of compounds containing sulfide skeleton structure and application thereof in preparation of phosphoglycolate dehydrogenase inhibitors.A series of novel PHGDH small molecule inhibitors containing sulfide skeleton are obtained by screening compound library and structural modification, which enriches the structure type and indications of PHGDH inhibitors.The application has the following technical effects: the application provides a kind of compounds as PHGDH inhibitors, tests show that it directly produces inhibitory effect on PHGDH, and finds an active small molecule with novel structure and good physicochemical properties, which shows good activity in various experiments and is expected to be developed into a specific drug treatment.

This invention relates to a genetically engineered bacterial strain that synthesizes indigo from glucose, its construction method, and its applications. The genetically engineered strain overexpresses indole-3-glycerol phosphate lyase derived from plants, and the α subunit of mono / dioxygenase and tryptophan synthase derived from bacteria. This application employs a genetic modification strategy, utilizing metabolic pathway enhancement and the integration of exogenous genes, to achieve the complete metabolism of glucose by *E. coli* to produce indigo. After 72 hours of shake-flask culture, the highest indigo yield can reach 3.11 g / L, reducing production costs and further promoting industrial production.

The application belongs to the technical field of genetic engineering, and particularly relates to a phosphoglycolate dehydrogenase mutant, an engineering bacterium and application of the engineering bacterium in L-serine production. The mutant contains a mutation of the 375th amino acid compared with a protein with an amino acid sequence as shown in SEQ ID NO:1. The mutant protein releases feedback inhibition, and the catalytic activity is significantly improved compared with the parent enzyme, thereby promoting the production of L-serine catalyzed by the phosphoglycolate dehydrogenase, and providing a new synthetic route and engineering bacterium for the production of L-serine.

The present application relates to the technical field of genetic engineering, and particularly relates to a recombinant bacteria with high yield of serine and application of the recombinant bacteria in fermentative production of serine. By knocking out ptsI gene of Escherichia coli, the present application blocks glucose PTS system, releases the association reaction between glucose transport and phosphorylation and PEP-pyruvate, and reduces the branch synthesis of pyruvate from serine synthesis precursor 3-phosphoglycerate. The present application further carries out growth adaptability evolution on the Escherichia coli with knocked out ptsI gene, and carries out sequencing on the obtained mutant strain, and the mutation is shown in Table 2. Finally, a chassis bacteria with accelerated growth rate is obtained. Then, by enhancing the expression of key serine genes serA, serB and serC of the mutant strain, and knocking out serine degradation pathway genes sdaA, sdaB and tdcG, the present application constructs an engineering bacteria for fermentative production of serine, and the serine yield of the engineering bacteria is significantly improved.

The application discloses a high-yield resveratrol Yarrowia lipolytica engineering strain and construction and application thereof, and belongs to the technical field of synthetic biology and metabolic engineering. The Yarrowia lipolytica engineering strain provided by the application can realize high-yield resveratrol by using glucose as a substrate, and the yield of resveratrol reaches 3.157 g / L in shake flask fermentation, and the yield of resveratrol is increased to 30.7 g / L in 5L scale batch feeding fermentation, which is the highest value reported at present.

The invention provides a resistance marker-free auxotrophic bacillus subtilis and a construction method and application thereof, the newly constructed strain takes bacillus subtilis 168 as a starting strain, indole-3-glycerophosphate synthase gene trpC of the bacillus subtilis 168 is knocked out, synthesis of tryptophan in the growth and metabolism process of the strain 168 is eliminated, and the resistance marker-free auxotrophic bacillus subtilis is obtained. The shuttle vector YH46 is constructed by taking pMD-19T as a framework, so that the shuttle vector YH46 can normally grow only in the presence of exogenous tryptophan, and meanwhile, a universal auxotroph shuttle vector YH46 is constructed by taking pMD-19T as the framework, so that convenience is provided for high-efficiency expression of genes in bacillus subtilis; the tryptophan auxotrophic strain BS-TR is constructed through double exchange by using a homologous recombination principle, the construction process is simple and easy to implement, and the strain BS-TR does not contain a resistance gene selection marker, can be used as a food-grade engineering bacterium, and can be used for intracellular expression or extracellular secretion of target protein for production.

The invention provides a method for synthesizing L-aspartic acid by catalyzing glycerol and CO2 through a biological enzyme. The method comprises the following steps: forming an in-vitro multi-enzyme catalysis system by using aldose oxidase, catalase-peroxidase, aldehyde dehydrogenase, 2-phosphoglycerol kinase, polyphosphate kinase, phosphoenolpyruvate hydratase, phosphoenolpyruvate carboxylase and aspartic dehydrogenase; and catalyzing the conversion of substrates into L-aspartic acid, wherein the substrates comprise glycerol, ammonium bicarbonate, ATP (adenosine triphosphate), polyphosphoric acid and other small amounts of inorganic salts. By optimizing the conditions of the cascade reaction, including pH, temperature, enzyme ratio and the like, the conversion of glycerol and CO2 into L-aspartic acid is catalyzed by the in-vitro multi-enzyme cascade reaction. The method disclosed by the invention is high in yield, high in purity, simple and convenient to operate and environment-friendly, the high-added-value product L-aspartic acid is produced by taking glycerol as an initial raw material, and meanwhile, the utilization of the mono-carbon compound also has the potential of solving the CO2 problem.

The application relates to a mutant enzyme of 3-phosphoglyceroyltransferase, a coding gene and application thereof, and belongs to the fields of biochemistry, molecular biology and metabolism. 58 GPAT9 mutant genes are constructed by using a site-directed mutagenesis technique, and the influence of single and multiple amino acid site changes on GPAT9 enzyme activity is analyzed by combining a GPAT-specific yeast genetic complementation method. It is found that the changes of six amino acid residues (85, 114, 119, 230, 237 and 322) located outside the acyltransferase conserved domain in AtGPAT9 can significantly affect the enzyme activity. There is interaction among the amino acids, for example, the simultaneous mutation of Y85W / N119H / S237N of the three sites can greatly increase the activity of AtGPAT9, accelerate the growth of yeast and promote the synthesis of triacylglycerol, and the triacylglycerol content in the yeast cells expressing the mutant enzyme is increased by 45.7% compared with that of the yeast cells expressing the wild type BnGPAT9.

The application provides a kit for culturing osteosarcoma organoids, the kit comprising a special culture medium, a sample dissociation digestive solution and a digestion termination solution, the special culture medium being based on a basic culture medium and adding dexamethasone, glycerophosphate disodium salt and calcium chloride, the osteosarcoma organoids carrying or not carrying an immune feature. The application also provides a culture method of the osteosarcoma organoids carrying the immune feature. The osteosarcoma organoids are cultured by using the culture method and the kit, the culture period is short, the stability is high, the in situ tumor heterogeneity can be reserved, the tumor microenvironment immune feature is stable, and the kit can be used for high-throughput drug screening, target gene identification, immunotherapy drug screening, oncolytic virus killing experiment, omics research such as single cell sequencing, and animal model construction. The application fills the blank of the interstitial-derived osteosarcoma organoid immune co-culture, and has a wide application prospect in the field of osteosarcoma basic research and clinical diagnosis and treatment.